INVO Fertility IVF
- Market cap
- $1.1M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.2×
- EV/EBIT
- n/m
- not a meaningful number
- Revenue, 12 months
- $7.5M
- +14% on a year ago
- Net margin
- −70.2%
- Free cash flow yield
- n/m
- not a meaningful number
INVO Fertility trades at 0.2× sales. Revenue was $7.5M over the last twelve months, up 14% on a year earlier with a −70% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $974.9K+314% | $1.4M+397% | $1.6M+353% | $1.8M+481% | $1.4M+47% | $1.7M+22% | $1.6M+4% | $1.9M+2% | $1.8M+23% | $1.6M−6% | $2M+23% | $2.2M+17% | |
| Cost of revenue | $581K+432% | $886.8K+1020% | $850.2K+268% | $861.6K+266% | $988.5K+70% | $957.4K+8% | $1M+23% | $1.1M+27% | $1.1M+14% | $1M+9% | $1.3M+23% | $1.4M+29% |
| Gross profit | $393.9K+212% | $495K+149% | $726.1K+521% | $974.9K+1116% | $444.7K+13% | $728.5K+47% | $592.3K−18% | $770.1K−21% | $629.3K+42% | $536.9K−26% | $727.8K+23% | $762.7K−1% |
| R&D | $2.7K−99% | $5.9K−92% | $4.9K−93% | $0 | $0 | $484.8K+8107% | $265.7K+5344% | n/a | n/a | n/a | n/a | n/a |
| SG&A | $1.3M−46% | $1.9M−30% | $1.4M−38% | $2.6M+30% | $1.5M+21% | $3.5M+87% | $1.6M+8% | $2.2M−17% | $2.1M+41% | $1.8M−48% | $2.2M+40% | $1.9M−13% |
| −$886.3K−65% | −$1.5M−45% | −$1.5M−35% | −$1.9M−10% | −$1.3M+47% | −$2M+30% | −$1.2M−21% | −$3M+61% | −$1.6M+26% | −$1.4M−28% | −$1.6M+33% | −$1.3M−57% | |
| Interest expense | $352.1K+19894% | $182K+224% | $181.3K−16% | $369.6K+111% | $273.6K−22% | $210.6K+16% | $307.8K+70% | $440.6K+19% | $145.8K−47% | $627.1K+198% | $180.3K−41% | $177.2K−60% |
| Pre-tax income | −$1.2M−51% | −$2M−29% | −$1.6M−38% | −$2.2M+0% | −$1.6M+29% | −$3.7M+87% | −$17.4M+991% | −$1.5M−31% | −$2.6M+65% | $1.9M | n/a | $944.9K |
| $1.9K | $23K+1012% | $1.8K | $0 | $29.3K+1451% | −$54K | n/a | n/a | n/a | n/a | n/a | $56.2K | |
| Net income | −$1.2M−51% | −$2M−28% | −$1.6M−37% | −$2.2M+0% | −$1.6M+31% | −$3.8M+90% | −$17.4M+990% | −$3.6M+61% | −$2.6M+62% | $2M | −$5.5M−68% | $888.7K |
| −$4032.00−83% | −$3686.40−86% | −$3624.00−85% | −$3582.40−80% | −$2417.60−40% | −$3936.00+7% | −$13895.72+283% | −$1456.92−59% | −$123.20−95% | n/a | −$13.52−100% | $1.40 | |
| 308+192% | 539+410% | 440+307% | 627+393% | 675+119% | 984+83% | 1.3K+185% | 2.5K+296% | 21.5K+3094% | n/a | 409.5K+32592% | 648K+25987% |
Gross profit: 14 periods, Q1 FY23 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 19 periods, Q4 FY11 to Q4 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: 13 periods, Q4 FY11 to Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 3 periods, Q3 FY12 to Q3 FY14: a loss quarter: its basic count, share-days: the 9-month average less the 6-month, weighted by days. Q2 FY15: a loss quarter: its basic count, share-days: the 6-month average less the 3-month, weighted by days. Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average over 366 days less the 9-month over 274, the two on one basis (x13.13).
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest INVO Fertility's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| IVFINVO Fertility | $1.1M | n/m | n/a | 0.2× | +14% | −70.2% | |
| BBLGBone Biologics | $1.3M | n/m | n/a | n/m | n/m | n/m | |
| TNONTenon Medical | $1.3M | n/m | n/a | 0.2× | +80% | n/m | |
| VJETFlyte Aviation | $846.1K | n/m | n/a | 0.4× | +219% | n/m | |
| AMIXAutonomix Medical | $1.6M | n/m | n/a | n/m | n/m | n/m | |
| NXGLNexgel | $1.8M | n/m | n/a | n/m | n/m | n/m | |
| ADGMAdagio Medical | $1.9M | n/m | n/a | n/a | n/m | n/a | |
| XAIRBeyond Air | $2.1M | n/m | n/a | 0.3× | +61% | n/m | |
| VVOSVivos Therapeutics | $2.2M | n/m | n/a | 0.1× | +45% | n/m | |
| CODXCo-Diagnostics | $2.2M | n/m | 6.0× | 3.1× | −28% | n/m | |
| BJDXBluejay Diagnostics | $592K | n/m | n/a | n/m | n/m | n/m | |
| Peer median | $1.7M | n/a | 6.0× | 0.3× | +61% | n/a |
More on INVO Fertility
Each number over time
Where it ranks
- #10of 497Healthcare stocks with the lowest price to sales ratio
- #3of 116Medical instruments and supplies stocks with the lowest price to sales ratio
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .